Overcoming PARP Inhibitor Resistance in an Olaparib-Induced Model
Poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as a promising therapeutic approach in the treatment of various cancers, particularly those...
Continue Reading
Poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as a promising therapeutic approach in the treatment of various cancers, particularly those...
Continue Reading
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a key mediator of non-canonical Wnt signaling and plays a critical role...
Continue Reading
Natural killer (NK) cells play a crucial role in the immune system and can recognize and kill cancer cells. Research...
Continue Reading
Antibody-Drug Conjugates (ADCs) have made significant advancements in cancer treatment, particularly for solid tumors. The bystander effect of ADCs, where...
Continue Reading
Cancers, like cervical cancer and head & neck cancer, are strongly linked to human papillomavirus (HPV) infection. Targeting the HPV...
Continue Reading
Antibody‒drug conjugates (ADCs), which combine the advantages of monoclonal antibodies with precise targeting and payloads, show great potential as cancer...
Continue Reading
From April 25 to 30, 2025, the annual meeting of the American Association for Cancer Research (AACR), one of the...
Continue Reading
At this year’s annual meeting of the American Association for Cancer Research (AACR), WuXi Biology has been selected to present...
Continue Reading
Synthetic lethality, where combining two non-lethal mutations results in cell death, is exploited in cancer therapy, with PARP inhibitors like...
Continue Reading